| Year |
Citation |
Score |
| 2019 |
Chen BJ, Dashnamoorthy R, Galera P, Makarenko V, Chang H, Ghosh S, Evens AM. The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma. Oncotarget. 10: 2030-2040. PMID 31007846 DOI: 10.18632/Oncotarget.26771 |
0.345 |
|
| 2019 |
Dashnamoorthy R, Sarkar S, Beheshti A, Mokhtar M, Konry T, Levin M, Evens AM. Transcriptomic and Metabolomic Profiling Identifies Calcium-Dependent Signaling Mechanisms As a Novel and Exploitable Target to Overcome Anti-CD20 Resistance in Non-Hodgkin Lymphoma (NHL) Blood. 134: 1511-1511. DOI: 10.1182/Blood-2019-126539 |
0.386 |
|
| 2019 |
Dashnamoorthy R, Beheshti A, Su X, Chen Y, Mokhtar M, Dolnikowski G, Lansigan F, Kinlaw WB, Dave S, Evens AM. Identification of FASN-Dependent Onco-Metabolic Regulation of the Pentose Phosphate Pathway (PPP) and Nucleotide Metabolism in Non-Hodgkin Lymphoma (NHL) Blood. 134: 1573-1573. DOI: 10.1182/Blood-2019-126382 |
0.514 |
|
| 2018 |
Dashnamoorthy R, Beheshti A, Sarkar S, Konry T, Levin M, Evens AM. Systems Biology Analyses to Delineate Mechanisms of Anti-CD20 Antibody Resistance in Non-Hodgkin Lymphoma (NHL): Influence of BCR Signaling and the Critical Importance of Calcium Polarization Blood. 132: 1665-1665. DOI: 10.1182/Blood-2018-99-118787 |
0.357 |
|
| 2018 |
Dashnamoorthy R, Beheshti A, Cass S, Kritharis A, Burgess K, London C, Evens AM. Transcriptomic Systems Biology Analyses with Buparlisib (BKM120) Pan PI3K Inhibition in Canine B Cell Lymphoma (BCL): Leveraging Comparative Oncology for Cancer Therapeutics and Biomarker Discovery Blood. 132: 4114-4114. DOI: 10.1182/Blood-2018-99-118548 |
0.473 |
|
| 2016 |
Zanotto-Filho A, Dashnamoorthy R, Loranc E, de Souza LH, Moreira JC, Suresh U, Chen Y, Bishop AJ. Combined Gene Expression and RNAi Screening to Identify Alkylation Damage Survival Pathways from Fly to Human. Plos One. 11: e0153970. PMID 27100653 DOI: 10.1371/Journal.Pone.0153970 |
0.538 |
|
| 2015 |
Passero FC, Dashnamoorthy R, Beheshti A, Hlatky L, Abermil N, Coyle ME, Sharma J, Evens AM. The Proteasome Inhibitor, Ixazomib, Combined with Novel Drug Combinations in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL): Identification of Key Genes and Signaling Pathways Via a Novel Systems Biology Approach Blood. 126: 2753-2753. DOI: 10.1182/Blood.V126.23.2753.2753 |
0.533 |
|
| 2015 |
Dashnamoorthy R, Beheshti A, Abermil N, Lansigan F, Kinlaw W, Gartenhaus R, Jones G, Hlatky L, Evens AM. Lipid Addiction of Diffuse Large B-Cell Lymphoma (DLBCL): Fatty Acid Synthase (FASN) and PI3K Dependent Cell Death Identifies a Novel Therapeutic Paradigm Blood. 126: 1284-1284. DOI: 10.1182/Blood.V126.23.1284.1284 |
0.478 |
|
| 2014 |
Dashnamoorthy R, Abermil N, Behesti A, Kozlowski P, Lansigan F, Kinlaw WB, Gartenhaus R, Jones G, Hlatky L, Evens AM. The Lipid Addiction of Diffuse Large B-Cell Lymphoma (DLBCL) and Potential Treatment Strategies with Novel Fatty Acid Synthase (FASN) Small Molecule Inhibitors Blood. 124: 4490-4490. DOI: 10.1182/Blood.V124.21.4490.4490 |
0.507 |
|
| 2014 |
Dashnamoorthy R, Behesti A, Abermil N, Sharma J, Coyle M, Kandela I, Mazar A, Hlatky L, Evens AM. Genome-Wide Analysis Reveals MYC-Dependent Cell Death and Identifies Predictive Biomarkers of Ixazomib Sensitivity in Preclinical Models of T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Blood. 124: 3120-3120. DOI: 10.1182/Blood.V124.21.3120.3120 |
0.47 |
|
| 2014 |
Kritharis A, Fowler T, Dashnamoorthy R, Burgess KE, Beheshti A, Abermil N, Roy A, Hlatky L, Pilichowska M, McNiel E, Evens AM. A Comparative Oncology Study of Canine and Human Genomics and Proteomics in Peripheral T-Cell Lymphoma (PTCL): Examination of Shared Oncogenic Signaling for Biomarker and Therapeutic Target Discovery Blood. 124: 3019-3019. DOI: 10.1182/Blood.V124.21.3019.3019 |
0.494 |
|
| 2014 |
Cerulli RA, Dashnamoorthy R, Evens AM. The Bruton’s Tyrosine Kinase Inhibitor CC-292 in Diffuse Large B-Cell Lymphoma (DLBCL), T-Cell Lymphoma (TCL), and Hodgkin Lymphoma (HL): Induction of Cell Death and Examination of Rational Novel/Novel Therapeutic Combinations Blood. 124: 1772-1772. DOI: 10.1182/Blood.V124.21.1772.1772 |
0.417 |
|
| 2013 |
Dashnamoorthy R, Lansigan F, Davis WL, Kinlaw WB, Gartenhaus R, Evens AM. Targeting The Interactions Of Fatty Acid Metabolism With PI3K/mTOR and MAPK As a Novel Therapeutic Strategy In Diffuse Large B-Cell Lymphoma (DLBCL) Blood. 122: 5133-5133. DOI: 10.1182/Blood.V122.21.5133.5133 |
0.493 |
|
| 2013 |
Dashnamoorthy R, Kandela I, Bhalla S, Mazar A. Evaluation Of Potency and The Associated Biology Of The Investigational Proteasome Inhibitor, Ixazomib: Redox, Autophagic, and MAPK-Dependent Cell Death In T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cell Lines and Human Lymphoma Xenograft Models Blood. 122: 4407-4407. DOI: 10.1182/Blood.V122.21.4407.4407 |
0.441 |
|
| 2012 |
Doderer MS, Anguiano Z, Suresh U, Dashnamoorthy R, Bishop AJ, Chen Y. Pathway Distiller - multisource biological pathway consolidation. Bmc Genomics. 13: S18. PMID 23134636 DOI: 10.1186/1471-2164-13-S6-S18 |
0.604 |
|
| 2012 |
Dashnamoorthy R, Kandela I, Bhalla S, Galloway J, Zaretsky I, Mazar A, Evens AM. The 2nd Generation Proteasome Inhibitor, MLN2238: Potent Induction of Cell Death in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cell Lines and in Two Human Lymphoma Xenograft Models. Blood. 120: 2767-2767. DOI: 10.1182/Blood.V120.21.2767.2767 |
0.415 |
|
| 2012 |
Dashnamoorthy R, Lansigan F, Davis WL, Kuemmerle N, Kinlaw WB, Evens AM. Fatty Acid Metabolism in Diffuse Large B-Cell Lymphoma (DLBCL): Interaction with Oncogenic Cell Signaling Pathways and the Identification of a Novel Treatment Paradigm. Blood. 120: 2711-2711. DOI: 10.1182/Blood.V120.21.2711.2711 |
0.5 |
|
| 2012 |
Dashnamoorthy R, Bhalla S, Crombie J, Kandela I, Mazar A, Evens AM. Darinaparsin in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cells Lines and SCID Xenograft Mouse Models: Single-Agent Activity and Synergistic Cell Death Combined with a PI3K/mTOR Inhibitor Blood. 120: 1646-1646. DOI: 10.1182/Blood.V120.21.1646.1646 |
0.433 |
|
| 2012 |
Lansigan F, Davis WL, Kuemmerle N, Lupien LE, Posternak V, Kaur P, Smits NC, Dashnamoorthy R, Evens AM, Kinlaw WB. Diffuse Large B-Cell Lymphomas Utilize Endogenous and Exogenous Fatty Acids for Cell Growth and Survival Blood. 120: 1581-1581. DOI: 10.1182/Blood.V120.21.1581.1581 |
0.433 |
|
| 2004 |
Das KC, Dashnamoorthy R. Hyperoxia activates the ATR-Chk1 pathway and phosphorylates p53 at multiple sites. American Journal of Physiology. Lung Cellular and Molecular Physiology. 286: L87-97. PMID 12959929 DOI: 10.1152/Ajplung.00203.2002 |
0.325 |
|
| Show low-probability matches. |